The FDA has declined to approve a closely watched lung-cancer drug from Summit Therapeutics. Regulators issued a complete response letter to the company. The decision blocks the drug’s path to market for now.
The agency told Summit that the treatment must show it helps patients live longer. Current data did not meet that standard. The drug needs stronger evidence of a survival benefit.
Summit had positioned the therapy as a potential rival in a competitive lung-cancer market. Investors had tracked its progress closely. The rejection marks a significant setback.
The FDA’s decision focused on overall survival as the key measure. Earlier trial results had raised questions about durability. Regulators sought clearer proof of extended lifespan.
Summit said it will review the agency’s feedback and determine next steps. Additional studies may be required to support approval. The company has not set a timeline for new data.
The drug remains unapproved in the United States. Patients currently rely on other available treatments. Summit has not announced plans to seek approval elsewhere.
Analysts expect the company to reassess its development strategy. Further trials would add time and cost. The path forward depends on generating stronger survival evidence.





